echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Simcere Pharma Appoints Zhou Gaobo as Chief Investment Officer

    Simcere Pharma Appoints Zhou Gaobo as Chief Investment Officer

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 17, Simcere announced the appointment of Zhou Gaobo as chief investment officer, responsible for the company's innovative drug investment and business expansion, new investment platform construction, and strategic planning and practice.
    He took office on the same day
    .

    Before joining Simcere, Mr.
    Gaobo Zhou served as a global managing partner and co-head of Greater China Healthcare Consulting at McKinsey & Company, and has fifteen years of experience in management consulting in the healthcare industry
    .


    Previously, he also worked on antibody and fusion protein drug development at Human Genome Sciences (HGSI)


    Mr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.